Saitama, Japan

Akifumi Kitahara


Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 1985

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Akifumi Kitahara: Innovator in Anti-Psychotic Drug Development

Introduction

Akifumi Kitahara is a notable inventor based in Saitama, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-psychotic drugs. His innovative work has led to the creation of new compounds that have the potential to improve mental health treatments.

Latest Patents

One of Akifumi Kitahara's key patents is titled "Phenothiazine derivatives and anti-psychotic drugs containing the same." This patent describes new phenothiazine derivatives characterized by a general formula where R represents a straight or branched alkyl group or alkenyl group having 5-15 carbon atoms, along with their acid addition salts and anti-psychotic drugs containing these new compounds. He holds 1 patent in this area, showcasing his expertise and innovation.

Career Highlights

Akifumi Kitahara is associated with Eisai Co., Ltd., a prominent pharmaceutical company known for its commitment to developing innovative medicines. His work at Eisai has allowed him to focus on research and development in the field of mental health, contributing to advancements in anti-psychotic therapies.

Collaborations

Throughout his career, Akifumi Kitahara has collaborated with esteemed colleagues such as Noriyasu Hirose and Shizuo Kuriyama. These collaborations have fostered a productive environment for innovation and have led to significant advancements in their shared field of expertise.

Conclusion

Akifumi Kitahara's contributions to the development of anti-psychotic drugs highlight his role as an important inventor in the pharmaceutical industry. His innovative work continues to pave the way for advancements in mental health treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…